Avidea Expands Scientific Advisory Board with Appointment of Prof. Dan Barouch, MD, PhD
BALTIMORE, Maryland – Avidea Technologies, Inc. (“Avidea”), a biotechnology company developing ‘precision’ immunotherapies for cancer and autoimmunity, announced today the appointment of Prof. Dan Barouch, MD, PhD, Professor of Medicine and Immunology at Harvard Medical School and Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, to Avidea’s scientific advisory board (SAB).
“We are excited to have Prof. Barouch join Avidea’s SAB,” said Andrew Ishizuka, Avidea’s CSO, “Prof. Barouch’s background and expertise in vaccinology will be invaluable as we advance vaccines in cancer and tolerance induction to the clinic and expand the applications for our SNAPvax platform to other disease areas.”
The appointment of Prof. Barouch expands Avidea’s SAB to five members with world-class expertise and backgrounds in the fields of vaccinology, immuno-oncology, tolerance induction, and bioengineering.
About Dan Barouch: Prof. Dan Barouch received his Ph.D. in immunology from Oxford University and his M.D. from Harvard Medical School. He is currently the William Bosworth Castle Professor of Medicine and Professor of Immunology at Harvard Medical School, Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, a member of the Ragon Institute of MGH, MIT, and Harvard, and part of the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery. His laboratory focuses on studying the immunology and virology of HIV-1 infection and developing novel vaccine and eradication strategies. His group has also applied their vaccine expertise to preclinical and clinical studies of other infectious diseases of global significance, including Zika virus, tuberculosis, and most recently SARS-CoV-2. His recent work contributed to the development of the single-shot Johnson & Johnson COVID-19 vaccine, which is now being rolled out in the United States and throughout the world. He was elected to the National Academy of Medicine in 2020.
About Avidea: Avidea is a private biotechnology company that is advancing the next generation of safer and more effective T cell immunotherapies for treating cancer and autoimmune diseases. Avidea’s precision immunotherapies are enabled by two polymer-drug conjugate technologies, SNAPvax and SyntholyticTM, which were purpose-built to address the need for improved T cell immunotherapies. The SNAPvax and Syntholytic platforms are enabling a pipeline of immunotherapies that will enter clinical testing in 2022 and 2023. For more information visit www.avideatechnologies.com.
Contact: Andrew Ishizuka, PhD, Avidea’s CSO, is available to comment.